Opdualag is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Opdualag is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameOpdualag
Authorized genericnivolumab and relatlimab-rmbw
Regular genericnivolumab and relatlimab-rmbw
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Opdualag?
The original
–
–

Brand nameThe maker’s card

BMS Access Support Co-Pay Assistance Program

Savings card from Bristol Myers Squibb

No insuranceNeeds insuranceNo cash price listed.
Insurance $0 a dose

Sign up on bmsaccesssupport.com 

Or call 1-800-861-0048.

In the maker’s words

“$0 Co-pay per dose…”

From the maker’s offer on bmsaccesssupport.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Opdualag itself, from the same company, sold without the brand name, and usually for less. For now Opdualag is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Opdualag is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Source: the FDA label for Opdualag (E.R. Squibb & Sons, L.L.C.), June 8, 2026. Full label on DailyMed 

Good to know